ORIGINAL RESEARCH article

Front. Endocrinol., 08 September 2025

Sec. Clinical Diabetes

Volume 16 - 2025 | https://doi.org/10.3389/fendo.2025.1546919

Diabetic Striate Syndrome: an uncommon complication of diabetes requiring further conceptual expansion

  • 1. Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China

  • 2. Department of Radiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China

  • 3. Department of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China

Abstract

Background:

Diabetic Striate Syndrome (DSS) is a rare complication of diabetes, clinically characterized by chorea-like involuntary movements and contralateral basal ganglia abnormalities on brain CT and MRI. The identification of atypical DSS cases has broadened our understanding of this complex metabolic disorder.

Objective:

To investigate the clinical manifestations, imaging features, and potential pathogenesis of DSS to enhance clinical awareness and understanding of the condition

Methods:

We retrospectively analyzed clinical data from eight patients diagnosed with DSS who were hospitalized in the Department of Neurology at Beijing Chaoyang Hospital, affiliated with Capital Medical University, between January 2017 and July 2024. Their clinical presentations and imaging findings were reviewed, and both typical and atypical features, as well as potential pathogenic mechanisms, were discussed in the context of relevant literature.

Results:

Among the eight patients, five were female. All patients had a history of hypertension, and seven had a prior diagnosis of diabetes. Three patients experienced acute or subacute cerebral infarction. Seven patients presented with hemichorea, while one patient exhibited bilateral chorea. Random blood glucose levels at onset ranged from 7.9 to 27.7 mmol/L, and glycated hemoglobin (HbA1c) levels ranged from 8.7% to 15.5%. One patient tested positive for urinary ketones, and one developed symptoms following a rapid drop in blood glucose. Head CT scans revealed high-density lesions in the basal ganglia in four patients. MRI showed T1-weighted hyperintensity in the basal ganglia in seven patients, including one case with bilateral involvement. Hospital stays ranged from 6 to 14 days. All patients showed clinical improvement, with one achieving complete resolution of symptoms. In three cases, symptom improvement was achieved through blood glucose control alone.

Conclusion:

DSS represents a syndrome with an expanding clinical and imaging spectrum as research progresses. In this study, we propose a refined definition of the disorder and reaffirm the hypothesis that both basal ganglia ischemia and hyperglycemia synergistically contribute to the development and progression of DSS.

1 Introduction

In outpatient and emergency settings, clinicians occasionally encounter patients presenting with chorea-like or ballismus movements in the context of hyperglycemia. This condition was predominantly observed in elderly individuals with diabetes and poorly glycemic control. The primary clinical manifestation was unilateral involuntary limb movements. Neuroimaging studies (, ) typically revealed hyperdensity in the contralateral basal ganglia on brain CT and T1-weighted hyperintensity in the same region on brain Magnetic Resonance Imaging (MRI). Urinary ketone bodies are usually negative, and symptoms generally improve or resolve following appropriate glycemic control.

Historically, Diabetic Striate Syndrome (DSS) has been referred to by various names, including diabetic striatopathy (), diabetic hemichorea/hemiballismus (, ), non-ketotic hyperglycemic hemichorea (). As clinical awareness of this disorder has grown, an increasing number of atypical cases have been reported. These include patients with positive ketone bodies, those presenting with clinical symptoms in the absence of characteristic imaging findings, individuals showing imaging abnormalities without overt symptoms, cases of chorea-like movements following rapid glycemic correction, and patients with non-choreiform involuntary movements (, , , ). To better capture the heterogeneous clinical and radiological presentations, some scholars over the past 15 years have advocated for the use of the term diabetic striatopathy, reflecting a broader and more inclusive understanding of the disorder. However, given the clinical and radiological heterogeneity of this condition, we propose the term DSS as a more inclusive and accurate designation.

This paper summarizes both the typical and atypical manifestations of DSS observed in patients treated at our hospital over the past seven years, and reviews recent literature to provide an updated perspective on the syndrome.

2 Materials and methods

2.1 Study subjects and methods

This study included eight patients diagnosed with DSS admitted to the Department of Neurology at our hospital between January 2017 and July 2024. The inclusion criteria were as follows: (1) a previous diagnosis of diabetes or a new diagnosis of diabetes upon admission; (2) the presence of choreiform involuntary movements; (3) characteristic imaging abnormalities. Exclusion criteria included other known causes of chorea, such as Wilson’s disease, Huntington’s disease, severe hepatic or renal dysfunction leading to involuntary movements, Sydenham’s chorea, thyroid disorders, severe electrolyte imbalances, toxic exposures, infections, and autoimmune diseases.

We collected general demographic information, clinical data, laboratory test results, and neuroimaging findings for each patient. Laboratory and imaging assessments included blood glucose, glycated hemoglobin (HbA1c), complete blood count, liver and kidney function tests, electrocardiogram (ECG), head computed tomography (CT), magnetic resonance imaging (MRI), and magnetic resonance angiography (MRA).

All imaging data were independently reviewed by a radiologist and a neurologist. The analysis focused on identifying lesion locations on CT and MRI, as well as detecting cerebrovascular abnormalities, such as arterial stenosis.

3 Results

3.1 General data

A total of eight patients were included in the study, five of whom were female (62.5%). The age of onset ranged from 50 to 88 years, with a mean age of 76.8 years. Seven patients had a pre-existing diagnosis of diabetes with a disease duration ranging from 6 to 20 years, while one patient was newly diagnosed upon admission. All patients had a history of hypertension. Additionally, four patients had a history of coronary artery disease, and three presented with renal function abnormalities. Two patients had acute cerebral infarction—one involving the ipsilateral basal ganglia and the other a lacunar infarction in the corpus callosum. Another patient had a subacute cerebral infarction.

Seven patients exhibited unilateral choreiform movements, while one patient presented with bilateral symptoms. The first patient had undergone a head MRI 45 days prior to the onset of chorea due to complaints of dizziness and fatigue; imaging revealed T1-weighted hyperintensity in the left basal ganglia. Choreiform movements developed after a rapid reduction in blood glucose levels. Similarly, the second patient experienced dizziness preceding the onset of chorea and had positive MRI findings. This patient also experienced a recurrence of symptoms one month after the initial episode.

Neurological examination revealed decreased muscle tone in four patients, positive pathological reflexes on the symptomatic side in two patients, and mildly reduced muscle strength in one patient. Further clinical details are provided in Table 1.

Table 1

CaseSexAge (years)Type of DMAge of diabetes diagnosisFBG on admission (mmol/l)HbA1c levels (%)Current medicationsFBG before discharge (mmol/l)Diabetes complications
1F742678.614Lixisenatide, Humalog8.3DPN, DR
2F822628.28.7Pioglitazone, Actos7.1DPN, DR, DN
3M5024411.915.5NovoRapid, Levemir5.3DPN, DR, ACI
4F8827219.514.6NovoLog, Levemir.7.7DPN, DR
5F812586.711.2Glucotrol, Acarbose.5.3DPN, DR, DN, ACI
6M692496.311.3NovoMix 30R, Metformin6DPN, DR, DF
7M8628559Repaglinide4.4DPN
8F842748.512.1Acarbose, Glipizide7.2DPN

Clinical characteristics of 8 cases with Diabetic Striate Syndrome.

DM, Diabetes Mellitus; FBG, fasting blood glucose; F, female; M, male; DPN, diabetic peripheral neuropathy; DN, diabetic nephropathy; DR, diabetic retinopathy; DF, diabetic foot; ACI, acute cerebral infarction.

3.2 Laboratory tests

At the time of symptom onset, random blood glucose levels among the eight patients ranged from 7.9 to 27.7 mmol/L. Fasting blood glucose levels ranged from 5.0 to 19.5 mmol/L, with a median value of 8.35 mmol/L. Glycated hemoglobin (HbA1c) levels ranged from 8.7% to 15.5%, with a median of 11.7%. Serum osmolality values were between 280 and 300 mOsm/L. One patient tested positive for urinary ketones. Detailed laboratory data are presented in Table 1.

3.3 Imaging findings

Routine head CT revealed abnormalities in the basal ganglia in four patients, one of whom did not exhibit corresponding lesions on T1-weighted MRI. Among the remaining seven patients, one demonstrated bilateral lesions on MRI. In two patients, the lesions involved both the caudate nucleus and the putamen, whereas in the other six patients, the lesions were confined to the putamen. On T2-weighted imaging, five patients showed slightly hypointense signals, two exhibited isointense signals, and one presented with slightly hyperintense signals. Diffusion-weighted imaging (DWI) revealed slightly hypointense or hypointense signals in six patients, while the remaining two had isointense signals. On susceptibility-weighted imaging (SWI), seven patients exhibited slightly hypointense signals in the affected basal ganglia regions, and one showed isointense signals. Six patients underwent magnetic resonance angiography (MRA), among whom five demonstrated varying degrees of stenosis in the middle cerebral artery (MCA) on the side corresponding to the lesion. Further details are presented in Table 2 and Figures 18.

Table 2

CaseBrain CTLocation of lesionMRIMCA stenosisAdditional medicationHospitalization duration (days)Course
T1T2DWISWI
1NormalCN, PNHSHSLSLYY7Improved
2PPNHSLSLSLY,BY14Improved
3PCN, PNHSLSLIYN12Improved
4PPNHSLSLSL/Y13Improved
5NormalPNHIISLYY6Improved
6PPNNIISLYN7Relieved
7NormalPNHSLLSLNormalY13Improved
8PPNHSLLSL/N7Improved

Imaging characteristics of 8 cases with Diabetic Striate Syndrome.

B, bilateral; CN, caudate nucleus; I, isointense signal; N, negative; P, positive; PN, putamen nucleus; H, high signal; SH, slightly high signal; L, low signal; SL, slightly low signal; Y, yes; N, no,/, not done.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

3.4 Treatment and outcomes

All eight patients received glycemic control as part of their treatment. Three patients were managed with glycemic control alone, while the remaining five received additional symptomatic therapy aimed at alleviating choreiform movements. Blood glucose management strategies were developed in consultation with endocrinologists. Patients in the table were listed in descending order of age. Notably, a shift in treatment patterns can be observed over time, with the medications used in more recent years differing from those administered in earlier cases. The duration of hospitalization ranged from 6 to 14 days. All patients experienced symptom improvement, with one patient achieving complete remission.

4 Special case reports

4.1 Case 1

A 74-year-old female patient was admitted with a chief complaint of “involuntary movement of the right lower limb for one week.” The symptoms were characterized by purposeless, uncontrollable twisting movements of the right lower limb, primarily involving flexion-extension at the proximal joints and rotational movements at the foot and ankle. The movements were continuous during wakefulness and subsided during sleep. Emergency brain CT showed no significant abnormalities. The patient’s fasting blood glucose on admission was 8.6 mmol/L.

Her past medical history included a 7-year history of diabetes, a 2-month history of hypertension (untreated), and recent intermuscular venous thrombosis of the lower limbs diagnosed one month prior. One month before admission, her random blood glucose level was 30 mmol/L, and her glycated hemoglobin (HbA1c) was 14%. She was initiated on insulin glargine, liraglutide, insulin lispro (Humalog), dapagliflozin, and pioglitazone. During this treatment, her blood glucose dropped to between 3.8 and 4.1 mmol/L.

Review of the patient’s medical history revealed that 45 days before hospitalization, she experienced dizziness and fatigue and underwent brain MRI in the neurology department. The MRI revealed hyperintensity in the left basal ganglia on T1-weighted imaging, slight hypointensity on T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences, and multiple enlarged perivascular spaces (EPVS) in the bilateral basal ganglia region on T2-weighted imaging. At that time, she did not present with involuntary movements. Neurological examination upon admission showed decreased muscle tone in the right limb, with no other significant abnormalities.

Laboratory tests after admission revealed a fasting blood glucose of 8.6 mmol/L and negative urine ketone bodies. Liver and kidney function tests, complete blood count, and electrolytes were within normal limits. A repeat brain MRI showed persistent hyperintensity in the left basal ganglia on the T1-weighted sequence, more pronounced than before, with slightly increased signal on the T2-weighted sequence and slight hypointensity on susceptibility-weighted imaging (SWI). Brain computed tomography angiography (CTA) demonstrated stenosis of the M1 segment of the left middle cerebral artery (MCA) and multiple sites of intracranial arterial stenosis. Following admission, the patient’s symptoms gradually improved with the addition of haloperidol (Figure 1).

4.2 Case 3

A 50-year-old male patient was admitted with a chief complaint of “involuntary movement of the right limbs for one week.” The symptoms were characterized by purposeless, uncontrollable movements involving both the right upper and lower limbs. The upper limb displayed flexion-extension of the arm, flinging movements, and wrist rotation. The lower limb showed proximal flexion-extension and distal foot and ankle rotation. The movements were continuous during wakefulness but diminished significantly or disappeared during sleep. Emergency brain CT revealed slightly increased density in the head of the left caudate nucleus, raising suspicion for hemorrhage, calcification, or abnormal substance deposition, along with multiple lacunar infarcts. The patient’s random blood glucose was 27.7 mmol/L, and urine ketone bodies were positive at 10 (+) mg/dl.

The patient had a 6-year history of hypertension, which was untreated, and a 6-year history of diabetes. He had previously taken glimepiride, although the dosage was unknown, and had discontinued the medication three months prior. He denied any history of stroke or coronary artery disease.

Neurological examination revealed decreased muscle tone in the right limbs, with no other notable findings. After admission, repeat random blood glucose was 33.8 mmol/L, HbA1c was 15.5%, urine glucose was (++++), and urine ketone bodies turned negative. Liver and kidney function tests, complete blood count, electrolytes, and thyroid function were within normal limits. On the third day of hospitalization, brain MRI revealed abnormal signals in the left basal ganglia, with findings on the T1-weighted sequence suggestive of possible acute infarction or hemorrhage. However, the lesion was not located in the caudate nucleus head. T2-weighted imaging showed scattered and relatively prominent enlarged perivascular spaces (EPVS) in the left basal ganglia region. Magnetic resonance angiography (MRA) indicated moderate to severe stenosis in the bilateral internal carotid arteries (C2–C6 segments), stenosis of the left middle cerebral artery (M1 segment), and multiple stenoses in the bilateral posterior cerebral arteries (P1–P2 segments). Susceptibility-weighted imaging (SWI) did not reveal hemorrhagic changes corresponding to the high-density lesion seen on CT in the caudate nucleus (Figure 3).

The patient received antiplatelet and lipid-lowering therapy. After five days of treatment, his fasting blood glucose decreased to 7.8 mmol/L, and 2-hour postprandial glucose levels ranged from 9.5 to 12.8 mmol/L. The involuntary movements improved significantly.

5 Discussion

DSS also known as diabetic striatopathy, diabetic non-ketotic hemichorea/hemiballism, was characterized by hyperglycemia associated with both chorea/ballism and contralateral striatal lesion. In 1960, Bedwell first reported this rare complication of diabetes (, ). Current research suggests that the incidence of this condition is less than 1 in 100,000 (). However, differing understandings of the condition among scholars may mean that this figure underestimates its true incidence.

The literature on this condition predominantly consists of retrospective case reports, which often adhere to the classical definition of DSS-namely, non-ketotic hyperglycemia, chorea, and contralateral basal ganglia hyperdensity on CT and/or T1-weighted hyperintensity on MRI. The lesions typically have well-defined borders and lack surrounding edema. The vast majority of case reports have used this classical definition of DSS, which involves the presence of involuntary movements and striatal abnormalities on imaging in patients with type 2 diabetes mellitus. Studies indicate that some patients exhibit involuntary movements without corresponding radiographic evidence, and such cases may not have been included in clinical reports. Because of the varying definitions of DSS among researchers, the epidemiological data for this condition remain inconsistent.

Over a decade ago, scholars proposed five subtypes of DSS (), including: the classical type; a type with symptoms and imaging changes but without hyperglycemia; non-ketotic hyperglycemia with symptoms but no imaging changes; non-ketotic hyperglycemia with imaging changes but no symptoms; and a type with non-ketotic hyperglycemia accompanied by bilateral symptoms and imaging changes.

Among the six cases we presented, several exhibited non-classic features. Some patients had radiographic lesions without corresponding symptoms (), while in case 1, chorea-like symptoms appeared following rapid glycemic control (). There have also been reports of patients with diabetes exhibiting typical DSS manifestations during hypoglycemic episodes. One possibility was that the striatum, being highly sensitive to changes in blood glucose levels, is particularly vulnerable to damage. The literature notes that chorea-like symptoms can persist for extended periods in some patients, however, recurrent episodes of chorea are rarely reported (). Our second patient experienced a recurrence of chorea-like symptoms one month after the initial episode. Co-occurrence with acute cerebral infarction has been previously reported (, , ). Our third, fifth and sixth patients had recent infarctions. Notably, the third patient had an acute cerebral infarction on the same side as the abnormal basal ganglia lesion, which has been rarely reported (, ). Furthermore, this patient’s initial urinalysis showed positive ketone bodies, which does not align with the classical DSS presentation. Clinically, patients presenting with bilateral chorea have also been observed (, ), as in our seventh patient. Interestingly, some patients with bilateral striatal lesions may exhibit only unilateral choreiform symptoms.

As more atypical cases have been reported, the definition of DSS warrants further expansion. Some scholars have proposed a broader definition of the condition (), characterizing it as a hyperglycemic state associated with at least one of the following: (1) chorea or ballism; (2) striatal hyperdensity on CT or hyperintensity on T1-weighted MRI. This definition already encompasses the majority of patients seen in clinical practice. However, there were still some patients who develop chorea-like symptoms after their blood glucose levels were lowered (, ). Additionally, individuals with diabetes may exhibit other types of involuntary movements, including hemifacial spasm, dystonia of the limbs, tremor, and dystonic disorders ().

We propose a slight revision to the current definition of DSS, patients with diabetes presenting with either of the following: (1) involuntary movement; (2) striatal hyperdensity on CT or hyperintensity on T1-weighted MRI. Furthermore, some researchers have suggested a classification system for diabetic striatopathy, dividing it into three subtypes (). However, given the rarity of this condition in clinical settings, our team believes that further subclassification may not be conducive to clinical research or practical diagnosis.

Currently, the most widely accepted theory regarding the pathogenesis of DSS was that metabolic disturbances in the striatum, caused by hyperglycemia. According to the metabolic abnormality theory, a reduction in γ-aminobutyric acid (GABA) levels leads to dysfunction of both the direct and indirect basal ganglia pathways, resulting in decreased inhibition of the thalamus. This disinhibition enhanced thalamo-cortical activity, ultimately producing chorea-like movements (, , ).

The emergence of atypical cases has prompted further discussion among scholars. Pathological studies have confirmed ischemia-like infarct changes in the striatal region (, ), suggesting that ischemia may also play a role in the pathogenesis of DSS. In our cases 3, 5, and 6, patients had recent cerebral infarctions, while in cases 1, 3, 5, 6, and 7, there was evidence of responsible vascular lesions or intracranial arterial stenosis. Additionally, enlarged perivascular spaces (EPVS) in the basal ganglia were observed in cases 1, 2, 3, 6, and 7. Currently, DSS is believed to occur predominantly in elderly patients with poorly controlled diabetes—a population also at high risk for ischemic cerebrovascular disease. Our patients exhibited EPVS, which are biomarkers of cerebral small vessel disease, as well as evidence of intracranial arterial stenosis, further supporting the potential role of cerebrovascular pathology in the development of DSS.

Based on previous research (, , ) and our case findings, we hypothesized that ischemic mechanisms contribute to the onset and progression of DSS. First, pathological evidence from earlier studies supports the presence of infarct-like changes in the basal ganglia region (, , ). Second, the basal ganglia are supplied by deep penetrating lenticulostriate arteries, which lack collateral circulation, rendering this region particularly susceptible to ischemia. In our cohort, most patients exhibited intracranial arterial stenosis, especially involving the middle cerebral artery. Finally, our patients commonly presented with risk factors for cerebrovascular disease, along with imaging evidence of small vessel disease in the basal ganglia. Some patients also had concurrent acute or subacute cerebral infarction.

Previous studies evaluating cerebrovascular conditions in DSS patients have been limited (), and to date, no reports have specifically assessed markers of cerebral small vessel disease such as EPVS. In our series, six patients underwent cranial MRA, with five showing middle cerebral artery stenosis. Additionally, most patients demonstrated EPVS in the basal ganglia region, with two cases classified as severe. These findings suggest that future evaluations of DSS patients should include assessment for both cerebral small vessel disease and large-vessel pathology.

Research on imaging findings in patients with DSS remains inconclusive. Various mechanisms have been proposed to explain the observed abnormalities, including petechial hemorrhage, infarction, myelinolysis, and calcium deposition (, ). Some pathological studies have also suggested a correlation between microbleeds and the characteristic imaging changes seen in DSS. Three studies (, , ) reported evidence of infarction in the basal ganglia region, two of them (, ) additionally identifying microbleeds and erythrocyte extravasation in the infarcted areas. In a study by Mestre et al., microbleeds were observed in the striatum, and the authors attributed the erythrocyte extravasation to blood-brain barrier dysfunction induced by hyperglycemia ().

However, the findings of a study utilizing the T2* sequence did not support the microbleeding hypothesis, as the T2* signal changes did not correspond to imaging features typically seen in focal hemorrhage (). Six patients with clinically documented hyperglycemia-induced hemichorea had undergone MR imaging with a T2*-based sequence. Among them, four exhibited unilateral hypointense signals within the striatum. Although SWI is currently considered highly sensitive for detecting microbleeds, none of our patients demonstrated microbleed-related signals on SWI sequences.

Based on previous literature and the characteristics observed in our case series, we believe that ischemia in the basal ganglia and hyperglycemia jointly contribute to the onset and progression of the disease.

6 Conclusion

As research advances, the clinical spectrum of diabetic striatopathy (DSS) continues to expand. We propose a revised definition of the syndrome and reaffirm that both basal ganglia ischemia and hyperglycemia play synergistic roles in its pathogenesis.

Statements

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by the institutional ethics committees of Beijing Chaoyang Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants’ legal guardians/next of kin because our study is a retrospective study. Informed consent was obtained from all patients prior to the imaging examinations, and all identifiable personal information was anonymized to protect patient privacy. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article because our study is a retrospective study. Informed consent was obtained from all patients prior to the imaging examinations, and all identifiable personal information was anonymized to protect patient privacy.

Author contributions

LYu: Data curation, Investigation, Writing – original draft, Writing – review & editing. HG: Conceptualization, Investigation, Writing – review & editing. WH: Supervision, Writing – review & editing. LYa: Data curation, Methodology, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research and/or publication of this article. This study was funded by Beijing Chaoyang Hospital, Capital Medical University, Research Funding (Project Approval Number: CYDXK202201).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Summary

Keywords

diabetes striatopathy, cerebral infarction, cerebral small vessel disease, etiology, chorea

Citation

Yu L, Gu H, Hu W and Yang L (2025) Diabetic Striate Syndrome: an uncommon complication of diabetes requiring further conceptual expansion. Front. Endocrinol. 16:1546919. doi: 10.3389/fendo.2025.1546919

Received

17 December 2024

Accepted

14 August 2025

Published

08 September 2025

Volume

16 - 2025

Edited by

Julián Benito León, University Hospital October 12, Spain

Reviewed by

Durjoy Lahiri, Queen’s University, Canada

Subhankar Chatterjee, Medical College and Hospital, Kolkata, India

Updates

Copyright

*Correspondence: Lei Yang,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics